The Journal of Heart and Lung Transplantation
Volume 27, Issue 3 , Pages 325-328 , March 2008

Performance of Limited Sampling Strategies for Predicting Mycophenolic Acid Area Under the Curve in Thoracic Transplant Recipients

  • Lillian S.L. Ting, MSc

      Affiliations

    • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Nilufar Partovi, PharmD, FCSHP

      Affiliations

    • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Pharmacy, Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • Robert D. Levy, MD, FRCPC

      Affiliations

    • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • Division of Respiratory Medicine, St. Paul’s Hospital and Vancouver General Hospital, Vancouver, British Columbia, Canada
    • The British Columbia Transplant Society, Vancouver, British Columbia, Canada
    • James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Andrew P. Ignaszewski, MD, FRCPC

      Affiliations

    • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • The British Columbia Transplant Society, Vancouver, British Columbia, Canada
    • Heart Function Clinic, St Paul’s Hospital, Providence HealthCare, Vancouver, British Columbia, Canada
    • ,
  • Mary H.H. Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS

      Affiliations

    • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Pharmacy, Children’s and Women’s Health Centre of British Columbia, Vancouver, British Columbia, Canada.
    • Corresponding Author InformationReprint requests: Mary H. H. Ensom, PharmD, Faculty of Pharmaceutical Sciences, University of British Columbia, c/o Pharmacy Department (OB7), Children’s and Women’s Health Center, Vancouver, BC V6H 6N1, Canada. Telephone: 604-875-3735. Fax: 604-875-3735.

References 

  1. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145–154
  2. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80(suppl):S244–S253
  3. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305–315
  4. Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid (A consensus panel report). Clin Biochem. 1998;31:317–322
  5. de Winter BC, Mathot RA, van Hest RM, van Geler T. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. Expert Opin Drug Metab Toxicol. 2007;3:251–261
  6. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419–430
  7. Baraldo M, Isola M, Feruglio MT, et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transplant Proc. 2005;37:2240–2243
  8. Wada K, Takada M, Kotake T, et al. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. Circ J. 2007;71:1022–1028
  9. Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH. Limited sampling strategy for predicting area under the concentration–time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy. 2006;26:1232–1240
  10. Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients. Ann Pharmacother. 2006;40:1509–1516
  11. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503–512
  12. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987–994
  13. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 1999;21:35–43
  14. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58
  15. Roche Laboratory, Inc.. CellCept (mycophenolate mofetil) drug monograph. 2003;March
  16. Billingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429–455

 Supported by the Canadian Institutes of Health Research (MOP #133946) and the Bong Pang Yee Endowment Fund, and a BC Medical Services Foundation Pre-Doctoral Fellowship (to L.S.L.T.), CIHR Canada Graduate Scholarships Doctoral Award (to L.S.L.T.) and the Michael Smith Foundation for Health Research Incentive Award (to L.S.L.T.). Analytical-grade mycophenolic acid was provided as a gift from Roche Palo Alto LLC.

PII: S1053-2498(07)01527-6

doi: 10.1016/j.healun.2007.12.009

The Journal of Heart and Lung Transplantation
Volume 27, Issue 3 , Pages 325-328 , March 2008

Article Tools